Abstract
Indications:For glycemic control in 4 patients with insulinoma.
AuthorsConclusions:In summary, the use of everolimus in four patients with insulinoma and refractory hypoglycemia was associated with improved glycemic control. The mechanisms underlying this observation would appear to warrant further investigation.
Patients:4 patients, a 57-year-old- female (case 1), a 40-year-old female (case 2), a 22-year-old female (case 3), and a 66-year-old male (case 4).
TypeofStudy:Case reports describing the substantial improvement in glycemic control and tumor regression after receiving Certican treatment in patients with insulinoma. Letters to the editor.
DosageDuration:Dosage and duration not stated.
Results:After receiving Certican treatment all 4 patients had remarkable improvement in glycemic control. 2 patients had tumor regression. In 2 remaining patients who did not have tumor regression, Certican may have a direct effect on glycemic control.
AdverseEffects:No adverse events were mentioned.
FreeText:Previous unsuccessful treatments: depot octreotide (case 1 and 4), radiofrequency ablation (case 1, 2, and 3), hepatic-artery chemoembolization (case 1 and 2), streptozocin plus doxorubicin (case 1 and 4), surgical debulking (case 2, 3, and 4), hepatic-artery embolization (case 2), 111-indium octreotide (case 1), resection of primary tumor, temozolomide plus bevacizumab (case 3), folinic acid/fluorouracil/oxaliplatin plus bevacizumab (case 4).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 195-197 |
| Number of pages | 3 |
| Journal | New England Journal of Medicine |
| Volume | 360 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 8 2009 |
ASJC Scopus subject areas
- General Medicine